Summary

Patients coinfected with hepatitis virus C (HCV) and HIV tend to respond poorly to interferon-based therapy and are at higher risk of treatment-related toxicities and adverse events. Treatment options are limited. There is some evidence that interferon-free therapy may work as well in patients who are HIV positive or negative. This article discusses a phase 2 study looking at the treatment option of sofosbuvir and the HCV NS5A inhibitor ledipasvir.